Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVM-1118 and Sorafenib in Advanced Hepatocellular Carcinoma
NCT03582618Phase 2Terminated
- Sponsor
- TaiRx, Inc.
- Start
- Jul 2018
- Primary completion
- Nov 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of dasatinib in hepatocellular carcinoma (HCC), sponsored by TaiRx, Inc.. Started Jul 2018; status: terminated.
02
Drugs
dasatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03582618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03582618.